A novel design of multi-epitope based vaccine against Escherichia coli
Micheal, A., Jimoh, A., Abiodun, A., Agboluaje, A., Aderinto, A., Aliu, T., Adesina, D., Komolafe, K., Olaoye, O. (2022). A novel design of multi-epitope based vaccine against Escherichia coli. EKB Journal Management System, 3(2), 407-419. doi: 10.21608/mid.2021.55310.1101
Adeoti O Micheal; Abdulwahab O Jimoh; Agoluaje Kabirat Abiodun; A K Agboluaje; A O Aderinto; Taiwo Sanusi Aliu; D A Adesina; K A Komolafe; O J Olaoye. "A novel design of multi-epitope based vaccine against Escherichia coli". EKB Journal Management System, 3, 2, 2022, 407-419. doi: 10.21608/mid.2021.55310.1101
Micheal, A., Jimoh, A., Abiodun, A., Agboluaje, A., Aderinto, A., Aliu, T., Adesina, D., Komolafe, K., Olaoye, O. (2022). 'A novel design of multi-epitope based vaccine against Escherichia coli', EKB Journal Management System, 3(2), pp. 407-419. doi: 10.21608/mid.2021.55310.1101
Micheal, A., Jimoh, A., Abiodun, A., Agboluaje, A., Aderinto, A., Aliu, T., Adesina, D., Komolafe, K., Olaoye, O. A novel design of multi-epitope based vaccine against Escherichia coli. EKB Journal Management System, 2022; 3(2): 407-419. doi: 10.21608/mid.2021.55310.1101

A novel design of multi-epitope based vaccine against Escherichia coli

Microbes and Infectious Diseases
Article 20, Volume 3, Issue 2, May 2022, Page 407-419  XML PDF (1000.86 K)
Document Type: Original Article
DOI: 10.21608/mid.2021.55310.1101
View on SCiNiTO View on SCiNiTO
Authors
Adeoti O Micheal email 1; Abdulwahab O Jimoh2; Agoluaje Kabirat Abiodun2; A K Agboluaje2; A O Aderinto2; Taiwo Sanusi Aliu2; D A Adesina3; K A Komolafe4; O J Olaoye2
1Department of Science Laboratory Technology, Microbiology option, The Oke- Ogun Polytechnic, Saki Oyo State . Department of Pure & Applied Biology, Ogbomoso Ladoke Akintola University of Technology. Cellular Parasitology Unit, Department of Zoology, University of Ibadan, Nigeria.
2Department of Science Laboratory Technology, Microbiology option, The Oke- Ogun Polytechnic, Saki Oyo State Nigeria
3Department of Microbiology and Botany, University of Ibadan, Ibadan, Nigeria
4Department of Science Laboratory Technology, Microbiology option, The Oke- Ogun Polytechnic, Saki Oyo State. Department of Zoology, Parasitology Unit, University of Ibadan, Nigeria
Abstract
Background: Multi-valent based vaccines have advantage over conventional vaccines because of its multi-faceted action targeted at antigen; thereby raising hope of a more sustained actions against allergens. Escherichia coli (E. coli) is a bacterium that is commonly found in the gut of humans and warm-blooded animals. An increasing number of outbreaks are associated with the consumption of fruits and vegetables (including sprouts, spinach, lettuce, coleslaw, and salad) thereby contamination may be due to contact with faeces from domestic or wild animals at some stages during cultivation or handling. Due to the reported increase in resistance to antibiotics used for Escherichia coli control; an effective vaccine is a would-be alternative of proven interest. Hence, a need for a rational, strategic, and efficient vaccine candidate against E.coli is of paramount necessity by the use of the most current bioinformatics tools to achieve this task. Method: In this study, immunoinformatics tools mined from diverse molecular databases were used  for a novel putative epitope based oral vaccine against E.coli. The prospective vaccine proteins were carefully screened and validated to achieve a high thorough-put three-dimensional protein structure. The eventual propsective vaccine candidate proteins was evaluated for its non-allergenicity, antigenicity, solubility, appropriate molecular weight testing and isoelectric point evaluation. Conclusion: The resultant vaccine candidate could serve as a promising anti-E.coli vaccine candidate. Immunoinformatics is a new field over pharmaco-therapeutics; this newest technology should continue to be a rescue from age-long traditional approach in vaccine developments.
Keywords
Immunoinformatics; Allergenicity; Pharmaco-therapeutics; Multi-epitope; Vaccine
Statistics
Article View: 402
PDF Download: 297